Abstract
BackgroundIn contrast to ORAL Surveillance data, reports from real world data did not show difference in rates of major adverse cardiovascular events (MACE) and malignancy between tofacitinib and biologic disease...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
